» Articles » PMID: 35441740

A Novel Prognostic Model Associated with the Overall Survival in Patients with Breast Cancer Based on Lipid Metabolism-related Long Noncoding RNAs

Overview
Journal J Clin Lab Anal
Publisher Wiley
Date 2022 Apr 20
PMID 35441740
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lipid metabolism is closely related to the occurrence and development of breast cancer. Our purpose was to establish a novel model based on lipid metabolism-related long noncoding RNAs (lncRNAs) and evaluate the potential clinical value in predicting prognosis for patients suffering from breast cancer.

Methods: RNA data and clinical information for breast cancer were obtained from the cancer genome atlas (TCGA) database. Lipid metabolism-related lncRNAs were identified via the criteria of correlation coefficient |R | > 0.4 and p < 0.001, and prognostic lncRNAs were identified to establish model through Cox regression analysis. The training set and validation set were established to certify the feasibility, and all samples were separated into high-risk group or low-risk group. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) were conducted to evaluate the potential biological functions, and the immune infiltration levels were explored through Cibersortx database.

Results: A total of 14 lncRNAs were identified as protective genes (AC022150.4, AC061992.1, AC090948.3, AC092794.1, AC107464.3, AL021707.8, AL451085.2, AL606834.2, FLJ42351, LINC00926, LINC01871, TNFRSF14-AS1, U73166.1 and USP30-AS1) with HRs < 1 while 10 lncRNAs (AC022150.2, AC090948.1, AC243960.1, AL021707.6, ITGB2-AS1, OTUD6B-AS1, SP2-AS1, TOLLIP-AS1, Z68871.1 and ZNF337-AS1) were associated with increased risk with HRs >1. A total of 24 prognostic lncRNAs were selected to construct the model. The patients in low-risk group were associated with better prognosis in both training set (p < 0.001) and validation set (p < 0.001). The univariate and multivariate Cox regression analyses revealed that risk score was an independent prognostic factors in both training set (p < 0.001) and validation set (p < 0.001). GO and GSEA analyses revealed that these lncRNAs were related to metabolism-related signal pathway and immune cells signal pathway. Risk score was negatively correlated with B cells (r = -0.097, p = 0.002), NK cells (r = -0.097, p = 0.002), Plasma cells (r = -0.111, p = 3.329e-04), T-cells CD4 (r = -0.064, p = 0.039) and T-cells CD8 (r = -0.322, p = 2.357e-26) and positively correlated with Dendritic cells (r = 0.077, p = 0.013) and Monocytes (r = 0.228, p = 1.107e-13).

Conclusion: The prognostic model based on lipid metabolism lncRNAs possessed an important value in survival prediction of breast cancer patients.

Citing Articles

OTUD6B-AS1: a multifaceted regulator of cancer with critical clinical implications.

Zheng Z, Zhou C, Yi F, Li J Am J Cancer Res. 2025; 15(1):1-18.

PMID: 39949926 PMC: 11815388. DOI: 10.62347/EHQK5961.


Disulfidptosis-related lncRNA signature to assess the immune microenvironment and drug sensitivity in acute myeloid leukemia.

Zhao Y, Cheng H, Wang J, Zang Y, Liu Z, Sun Y Sci Rep. 2024; 14(1):32015.

PMID: 39738722 PMC: 11685725. DOI: 10.1038/s41598-024-83560-8.


The metabolism-related lncRNA signature predicts the prognosis of breast cancer patients.

Ge X, Lei S, Wang P, Wang W, Wang W Sci Rep. 2024; 14(1):3500.

PMID: 38347041 PMC: 10861477. DOI: 10.1038/s41598-024-53716-7.


Comprehensive analysis of ICD-related lncRNAs in predicting risk stratification, clinical prognosis and immune response for breast cancer.

Wang Y, Yue T, He Q Aging (Albany NY). 2023; 15(17):8833-8850.

PMID: 37695742 PMC: 10522379. DOI: 10.18632/aging.205002.


Characterization and Prognosis of Biological Microenvironment in Lung Adenocarcinoma through a Disulfidptosis-Related lncRNAs Signature.

Yang Z, Cao S, Wang F, Du K, Hu F Genet Res (Camb). 2023; 2023:6670514.

PMID: 37575978 PMC: 10421709. DOI: 10.1155/2023/6670514.


References
1.
Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

2.
Li P, Li R, Huang Y, Lu J, Zhang W, Wang Z . LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability. Aging (Albany NY). 2021; 13(21):24171-24191. PMC: 8610138. DOI: 10.18632/aging.203672. View

3.
Shi G, Zhou Q, Zhu Q, Wang L, Jiang G . A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs. J Clin Lab Anal. 2022; 36(6):e24384. PMC: 9169174. DOI: 10.1002/jcla.24384. View

4.
Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

5.
Yang M, Qin Q, Zhu J, Guo Y, Yin T, Wu H . Long noncoding RNA ITGB2-AS1 promotes growth and metastasis through miR-4319/RAF1 axis in pancreatic ductal adenocarcinoma. J Cell Physiol. 2020; . DOI: 10.1002/jcp.29471. View